Latest reported quarter: ANNUAL, ended Dec 2025
Quarter 2026/Q2
| Line item | 2025 ANNUAL | 2024 ANNUAL | 2023 ANNUAL | 2022 ANNUAL | 2021 ANNUAL |
|---|---|---|---|---|---|
| Total Revenue as Reported | $930.00M | $787.20M | $670.60M | $680.70M | $569.97M |
| Total Operating Revenue | $930.00M | $787.20M | $670.60M | $680.70M | $569.97M |
| Cost of Revenue | $544.70M | $452.40M | $415.30M | $443.20M | $352.04M |
| Gross Profit | $385.30M | $334.80M | $255.30M | $237.50M | $217.93M |
| Operating Expense | $128.20M | $102.60M | $94.10M | $94.60M | $86.82M |
| Depreciation & Amortization & Depletion | $91.70M | $65.70M | $65.50M | $69.00M | $62.66M |
| -Depreciation & Amortization | $91.70M | $65.70M | $65.50M | $69.00M | $62.66M |
| Other Taxes | $36.50M | $36.90M | $28.60M | $25.60M | $24.16M |
| Operating Profit | $257.10M | $232.20M | $161.20M | $142.90M | $131.11M |
| Net Non-Operating Interest Income (Expense) | -$72.50M | -$68.40M | -$36.90M | -$24.40M | -$20.14M |
| Non-Operating Interest Expense | $72.50M | $68.40M | $36.90M | $24.40M | $20.14M |
| Other Income (Expense) | $8.40M | -$2.00M | -$9.00M | $5.10M | $1.72M |
| Special Income (Charges) | -$1.20M | -$4.00M | -$10.40M | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $1.20M | $4.00M | $10.40M | $0.00 | $0.00 |
| Other Non-Operating Income (Expenses) | $9.60M | $2.00M | $1.40M | $5.10M | $1.72M |
| Pretax Profit | $193.00M | $161.80M | $115.30M | $123.60M | $112.70M |
| Tax | $52.70M | $43.20M | $28.10M | $33.80M | $29.23M |
| Net Profit | $140.30M | $118.60M | $87.20M | $89.80M | $83.47M |
| Profit from Continuing Operations | $140.30M | $118.60M | $87.20M | $89.80M | $83.47M |
| Net Income to Parent Company | $140.30M | $118.60M | $87.20M | $89.80M | $83.47M |
| Net Income to Common Stockholders | $140.30M | $118.60M | $87.20M | $89.80M | $83.47M |
| Basic EPS | $6.00 | $5.28 | $4.75 | $5.07 | $4.75 |
| Diluted EPS | $5.97 | $5.26 | $4.73 | $5.04 | $4.73 |
| Dividend Per Share | $2.70 | $2.51 | $2.31 | $2.09 | $1.88 |
No comments yet — be the first to weigh in on CPK.